Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.64 |
| ▸ | PHGDH | O43175 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17527479 | 0.94 | BTK (0.58) | BTKPIK3CDPIK3R1PIK3CA | |
| SCHEMBL17527480 | 0.94 | BTK (0.58) | BTKPIK3CDPIK3R1PIK3CA | |
| SCHEMBL17545850 | 0.92 | BTK (0.52) | BTKPHGDHPIK3CDPIK3R1PIK3CA | |
| SCHEMBL17527474 | 0.91 | BTK (0.52) | BTKPIK3CDPIK3R1PIK3CAKMT2A | |
| SCHEMBL17527472 | 0.91 | BTK (0.52) | BTKPIK3CDPIK3R1PIK3CAKMT2A | |
| SCHEMBL17527332 | 0.91 | BTK (0.65) | BTK | |
| SCHEMBL17527333 | 0.91 | BTK (0.65) | BTK | |
| SCHEMBL17545848 | 0.90 | BTK (0.63) | BTKPIK3CDPIK3CA | |
| SCHEMBL17545841 | 0.87 | BTK (0.47) | BTKPIK3CDPIK3R1KCNH2 | |
| SCHEMBL17527452 | 0.87 | BTK (0.49) | BTKPIK3CDPIK3R1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | BTK 4/4885PHGDH 2489/4885PIK3CD 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.